<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03612856</url>
  </required_header>
  <id_info>
    <org_study_id>3G3-18-02</org_study_id>
    <nct_id>NCT03612856</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy/Potency of a Single Dose of Xisomab 3G3, Administered at the Beginning of a Regular Hemodialysis Procedure, in Patients With End-Stage Renal Disease on Chronic Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aronora, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aronora, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of AB023 (xisomab 3G3) in patients with end
      stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two
      cohorts. Within each cohort the patients will be randomized to receive either AB023 (xisomab
      3G3) or placebo (at a ratio of 2:1 active: placebo).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Actual">July 6, 2019</completion_date>
  <primary_completion_date type="Actual">July 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Subjects With Treatment-related Adverse Events (TEAEs) and the Number of TEAEs Will be Summarized Using Frequency Counts (Safety and Tolerability)</measure>
    <time_frame>21 days</time_frame>
    <description>TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Bleeding at the HD Vascular Access Site (Safety and Tolerability)</measure>
    <time_frame>21 days</time_frame>
    <description>The number of patients with clinically relevant and non-major bleeding events from the vascular access site. Bleeding from the access site was assessed immediately following decannulation. Pressure was placed on the access site for 10 min. After 10 minutes, the access site was checked for bleeding. If still bleeding, pressure was applied for another 5 minutes and checked again. This was repeated until hemostasis was achieved and the time to hemostasis was recorded. A time greater than 10 min was considered a non-major bleeding event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability).</measure>
    <time_frame>21 days</time_frame>
    <description>12-lead electrocardiogram measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects That Develop Treatment-related Immunogenicity Will be Summarized Using Frequency Counts (Safety and Tolerability).</measure>
    <time_frame>21 days</time_frame>
    <description>Immunogenicity measured by the presence of plasma anti-drug antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed.</measure>
    <time_frame>21 days</time_frame>
    <description>Body temperature will be measured in degrees Celsius.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed.</measure>
    <time_frame>21 days</time_frame>
    <description>Respiratory rate will be measured in breaths per minute.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed.</measure>
    <time_frame>21 days</time_frame>
    <description>Systolic and diastolic blood pressure will be measured in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed.</measure>
    <time_frame>21 days</time_frame>
    <description>Heart rate will be measured in beats per minute.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Plasma aPTT will be measured in seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Prothrombin time will be measured in seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Bilirubin (total and direct) levels in the blood will be measured in mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Alkaline phosphatase levels in the blood will be measured in U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>AST levels in the blood will be measured in U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>ALT levels in the blood will be measured in U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>LDH levels in the blood will be measured in U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Albumin levels in the blood will be measured in g/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Sodium levels will be measured in mEq/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Potassium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Potassium levels will be measured in mEq/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Chloride Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Chloride levels will be measured in mEq/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Blood glucose levels will be measured in mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Creatinine Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Creatinine levels will be measured in mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Hemoglobin levels will be measured in g/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Hematocrit Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Hematocrit levels will be measured in %.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Total leukocyte counts will be measured in 10˄3/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Differential leukocyte counts will be measured in %.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Red blood cell count will be measured in 10˄6/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Platelet Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</measure>
    <time_frame>21 days</time_frame>
    <description>Platelet count will be measured in 10˄3/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine pH, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>pH of the urine will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>Specific gravity of the urine will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine Protein Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>Protein levels in the urine will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>Glucose levels in the urine will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>Ketone levels in the urine will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>Bilirubin levels in the urine will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine Blood Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>Blood levels in the urine will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>Nitrite levels in the urine will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>Urobilinogen levels in the urine will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</measure>
    <time_frame>21 days</time_frame>
    <description>Leukocyte esterase levels in the urine will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome).</measure>
    <time_frame>21 days</time_frame>
    <description>Assessment of thrombus accumulation in the dialyzer cartridge measured by visual inspection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome).</measure>
    <time_frame>21 days</time_frame>
    <description>Assessment of BUN (mg/dL) before and after hemodialysis as urea reduction ratio (URR), %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV.</measure>
    <time_frame>21 days</time_frame>
    <description>Assessment of BUN (mg/dL) before and after hemodialysis as KtV (mL/min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome).</measure>
    <time_frame>21 days</time_frame>
    <description>Assessment of plasma potassium (mEq/L) before and after hemodialysis. The reduction of plasma potassium (before hemodialysis minus after hemodialysis) is reported in mEq/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis Efficiency as Measured by Length of the Hemodialysis Session (Pharmacodynamic Outcome).</measure>
    <time_frame>21 days</time_frame>
    <description>The length of each hemodialysis session will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of a Single Intravenous Dose of Xisomab 3G3 on the Activated Partial Thromboplastin Time (aPTT) (Pharmacodynamic Outcome).</measure>
    <time_frame>21 days</time_frame>
    <description>aPTT will be measured as a pharmacodynamic marker and the change from baseline will be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Maximum Plasma Concentration (Cmax) of Xisomab 3G3 After a Single Injection Will be Measured in Each Patient (Pharmacokinetic Outcome).</measure>
    <time_frame>14 days</time_frame>
    <description>Maximum plasma concentration of xisomab 3G3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time to Reach Maximum Plasma Concentrations of Xisomab 3G3 (Tmax) After a Single Injection Will be Measured in Each Patient (Pharmacokinetic Outcome).</measure>
    <time_frame>14 days</time_frame>
    <description>The time to reach maximum plasma concentrations of xisomab 3G3 after a single injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Patient (Pharmacokinetic Outcome)</measure>
    <time_frame>14 days</time_frame>
    <description>The area under the plasma concentration-time curve from time 0 to the last measurable non-zero concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Patient (Pharmacokinetic Outcome).</measure>
    <time_frame>14 days</time_frame>
    <description>The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of AUC0-inf Extrapolated (AUC%Extrap) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Patient (Pharmacokinetic Outcome).</measure>
    <time_frame>14 days</time_frame>
    <description>The percent of AUC0-inf extrapolated (AUC%extrap) is calculated by (1-AUC0-t/AUC0-inf)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent First Order Terminal Elimination Rate Constant (Kel) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject (Pharmacokinetic Outcome).</measure>
    <time_frame>14 days</time_frame>
    <description>The apparent first order terminal elimination rate constant will be calculated from a semi-log plot of the plasma concentration versus time curve. The parameter will be calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent First Order Terminal Elimination Half-life (T1/2) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Patient (Pharmacokinetic Outcome).</measure>
    <time_frame>14 days</time_frame>
    <description>The apparent first order terminal elimination half-life will be calculated as 0.693/Kel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent Total Plasma Clearance (CL) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Patient (Pharmacokinetic Outcome).</measure>
    <time_frame>14 days</time_frame>
    <description>The apparent total plasma clearance will be calculated as [Dose/AUC0-inf].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total Apparent Volume of Distribution (Vss) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Patient (Pharmacokinetic Outcome).</measure>
    <time_frame>14 days</time_frame>
    <description>The total apparent volume of distribution (Vss) will be calculated as the mean residence time x clearance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>AB023 (xisomab 3G3)- Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AB023 (xisomab 3G3)- Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single dose of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB023- Dose 1</intervention_name>
    <description>Participants will receive a single dose of 0.25 mg/kg AB023.</description>
    <arm_group_label>AB023 (xisomab 3G3)- Dose 1</arm_group_label>
    <other_name>xisomab 3G3- Dose 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB023-Dose 2</intervention_name>
    <description>Participants will receive a single dose of 0.5 mg/kg AB023.</description>
    <arm_group_label>AB023 (xisomab 3G3)- Dose 2</arm_group_label>
    <other_name>xisomab 3G3- Dose 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Participants will receive a single dose of placebo.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must fulfill all of the following inclusion criteria to be eligible for
        participation in the study:

          1. ESRD maintained on stable outpatient HD regimen, using an established (&gt; 3 months) and
             normally functioning, regular flow, uninfected first mature AV fistula (or AV graft)
             and skin consistent with standard chronic HD access injuries, and HD stability defined
             as Kt/V ≥ 1.2 within 3 months prior to screening at a healthcare center for &gt; 3 months
             from screening.

          2. On HD regimen at least 3 times per week for a minimum of 3 hours per dialysis session,
             using a complication-free well maintained AV fistula (or AV graft), expected and plan
             to continue this throughout and for at least 3 months beyond the study.

          3. Is capable of understanding the written informed consent, provides signed and
             witnessed written informed consent, and agrees to comply with protocol requirements
             and study related procedures.

          4. Willing to be confined to the CRU for the duration of the study, able to comply with
             all study-related requirements, and able to adhere to study restrictions and visit
             schedules.

          5. Male or female, between 18 and 80 years of age (inclusive) at the time of screening.

          6. BMI of ≥ 18 at the time of screening.

          7. Considered by the PI to be clinically stable with respect to underlying ESRD, based on
             medical evaluation that includes medical and surgical history, and a complete physical
             examination including vital signs, ECG, and clinical laboratory test results at
             screening. Repeat assessments are permitted for any laboratory, ECG, or vital sign
             parameter required for enrollment.

          8. Female patients must be of non-childbearing potential and must have undergone one of
             the following:

               -  sterilization procedures at least 6 months prior to dosing:

               -  hysteroscopic sterilization;

               -  bilateral tubal ligation or bilateral salpingectomy;

               -  hysterectomy;

               -  bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year
                  prior to dosing and follicle stimulating hormone (FSH) serum levels consistent
                  with postmenopausal status as per PI or designee judgment.

          9. Male patients must either be sterile (vasectomy with history of a negative sperm count
             following the procedure); practice total abstinence from sexual intercourse as the
             preferred lifestyle (periodic abstinence is not acceptable); use a male condom with
             any sexual activity; or agree to use a birth control method considered to be
             appropriate by the Investigator (such as one of the methods identified above for
             female patients) from the time of screening until 90 days after study drug
             administration. Male patients must agree not to donate sperm for a period of 90 days
             after study drug administration.

        Exclusion Criteria:

        Patients must not be enrolled in the study if they meet any of the following criteria:

          1. Documented history of acute vasoocclusive thrombotic event (acute coronary syndrome,
             stroke or transient ischemic attack, venous thromboembolic event), or vascular access
             fistula or AV graft failure in the past 3 months.

          2. With the exception of unfractionated heparin during HD, concomitant or prior use of
             anticoagulant/antiplatelet agents (e.g., low molecular weight heparins, warfarin,
             apixaban, bivalirudin, ticagrelor, edoxaban, dabigatran, rivaroxaban, clopidogrel,
             prasugrel, ticlopidine, eptifibatide, tirofiban, dipyridamole, diclofenac, and all
             other NSAIDs) that may affect hemostasis for 2 weeks prior to check-in on Day -8 and
             throughout the study.

          3. Use of unfractionated heparin for HD sessions from check-in on Day -8 and throughout
             the study.

          4. Any clinically significant (CS) concomitant disease or condition (including treatment
             for such conditions) that, in the opinion of the PI, could either interfere with the
             study drug, compromise interpretation of study data, or pose an unacceptable risk to
             the patient.

          5. Any other CS abnormalities in laboratory test results at screening that would, in the
             opinion of the PI, increase the patient's risk of participation, jeopardize complete
             participation in the study, or compromise interpretation of study data.

          6. Pregnant (positive pregnancy test) at screening or check-in on Day -8. If serum human
             chorionic gonadotropin (hCG) pregnancy test results are indeterminate, follow-up
             testing should be performed to determine eligibility.

             All female patients will not be pregnant and will have a negative pregnancy test at
             screening and check-in on Day -8, with the following exception: females receiving
             dialysis with an indeterminate pregnancy test result or persistently low hCG resulting
             in a false positive pregnancy test may be included in the study at the discretion of
             the PI. Postmenopausal patients with a result outside the postmenopausal range or an
             indeterminate pregnancy test will undergo additional testing with FSH to confirm
             postmenopausal status prior to study enrollment.

          7. Treatment with another investigational drug or device study within 30 days (or 5 half
             lives, whichever is longer) prior to check-in on Day -8.

          8. Acute illness that is considered by the PI to be CS within 2 weeks of check-in on Day
             8.

          9. Currently have established underlying inherited or acquired symptomatic bleeding
             disorders and/or are at risk for excessive bleeding per PI judgment or current active
             bleeding (e.g., gastrointestinal, intracranial), aside from minor bleeding from the
             puncture site on the AV fistula or AV graft, which would be expected to occur during
             the dialysis procedure, with the following values:

               -  Platelet count &lt; 100,000 cells/mm3 (if &lt; 100,000 but &gt; 75,000 cells/mm3, with
                  permission of PI and medical monitor) at screening

               -  INR &gt; 1.4 at screening

               -  aPTT up to 1.2 x ULN (if &gt;1.2x ULN up to &lt; 1.5 x ULN, with permission of PI and
                  medical monitor) at screening

               -  ALT or AST &gt; 2 x ULN at screening

               -  Total bilirubin &gt; 1.2 ULN at screening

               -  Hemoglobin concentration &lt; 10 g/dL at screening

         10. Seated blood pressure &lt; 90/40 mmHg at screening and check-in on Day -8.

         11. Exclusion criteria for ECG at screening and check-in on Day -8:

             Heart rate &lt; 45 and &gt; 110 bpm QTcF interval &gt; 500 msec (bpm = beats per minute; msec =
             milliseconds; QTcF = QT interval corrected using Fridericia's formula)

               -  Any significant arrhythmia or conduction abnormality, (including but not specific
                  to atrioventricular block [2nd degree or higher], Wolff Parkinson White syndrome
                  [unless curative radio ablation therapy]), which, in the opinion of the PI and
                  Medical Monitor, could interfere with the safety for the individual patient.

               -  Non-sustained or sustained ventricular tachycardia (&gt; 2 consecutive ventricular
                  ectopic beats at a rate of &gt; 1.7/second).

         12. History of a CS allergy to recombinant biologic drug, rodents, or a known sensitivity
             or idiosyncratic reaction to any compound present in xisomab 3G3, its related
             compounds, or any compound listed as being present in the study formulation.

         13. Participate in strenuous exercise from 48 hours prior to check-in on Day -8 and
             throughout the study.

         14. Positive test for drugs of abuse and/or positive alcohol test at screening or check in
             on Day 8 if not accounted for by a prescription medication. Patients with a positive
             test based on a prescribed medication may be enrolled.

         15. Positive test at screening for hepatitis B surface antigen (HBsAg) or human
             immunodeficiency virus (HIV). If a patient with ESRD has positive test results for
             hepatitis C virus (HCV) but liver function tests are otherwise not clinically
             significant, the patient may be included at the PI's discretion.

         16. Receiving blood purification therapy other than HD.

         17. Any other reason that would render the patient unsuitable for study enrollment at the
             discretion of the PI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <results_first_submitted>July 6, 2020</results_first_submitted>
  <results_first_submitted_qc>July 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2020</results_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03612856/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03612856/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03612856/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 37 participants were screened for the study, of which 10 did not meet eligibility criteria. The remaining 27 participants were enrolled. 3 participants terminated the study prior to randomization either by withdrawing consent or at the PI's discretion. The remaining 24 participants were randomized into the study and dosed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AB023 (Xisomab 3G3)- Dose 1</title>
          <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
        </group>
        <group group_id="P2">
          <title>AB023 (Xisomab 3G3)- Dose 2</title>
          <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre-dose Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-dose Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AB023 (Xisomab 3G3)- Dose 1</title>
          <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
        </group>
        <group group_id="B2">
          <title>AB023 (Xisomab 3G3)- Dose 2</title>
          <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="7.59"/>
                    <measurement group_id="B2" value="53.1" spread="5.30"/>
                    <measurement group_id="B3" value="52.6" spread="9.21"/>
                    <measurement group_id="B4" value="53.8" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Treatment-related Adverse Events (TEAEs) and the Number of TEAEs Will be Summarized Using Frequency Counts (Safety and Tolerability)</title>
        <description>TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Treatment-related Adverse Events (TEAEs) and the Number of TEAEs Will be Summarized Using Frequency Counts (Safety and Tolerability)</title>
          <description>TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Bleeding at the HD Vascular Access Site (Safety and Tolerability)</title>
        <description>The number of patients with clinically relevant and non-major bleeding events from the vascular access site. Bleeding from the access site was assessed immediately following decannulation. Pressure was placed on the access site for 10 min. After 10 minutes, the access site was checked for bleeding. If still bleeding, pressure was applied for another 5 minutes and checked again. This was repeated until hemostasis was achieved and the time to hemostasis was recorded. A time greater than 10 min was considered a non-major bleeding event.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Bleeding at the HD Vascular Access Site (Safety and Tolerability)</title>
          <description>The number of patients with clinically relevant and non-major bleeding events from the vascular access site. Bleeding from the access site was assessed immediately following decannulation. Pressure was placed on the access site for 10 min. After 10 minutes, the access site was checked for bleeding. If still bleeding, pressure was applied for another 5 minutes and checked again. This was repeated until hemostasis was achieved and the time to hemostasis was recorded. A time greater than 10 min was considered a non-major bleeding event.</description>
          <units>non-major bleeding event at access site</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose hemodialysis days (days -7, -5, -3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose hemodialysis days (days 1, 3, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability).</title>
        <description>12-lead electrocardiogram measurement</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability).</title>
          <description>12-lead electrocardiogram measurement</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects That Develop Treatment-related Immunogenicity Will be Summarized Using Frequency Counts (Safety and Tolerability).</title>
        <description>Immunogenicity measured by the presence of plasma anti-drug antibodies</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects That Develop Treatment-related Immunogenicity Will be Summarized Using Frequency Counts (Safety and Tolerability).</title>
          <description>Immunogenicity measured by the presence of plasma anti-drug antibodies</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed.</title>
        <description>Body temperature will be measured in degrees Celsius.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed.</title>
          <description>Body temperature will be measured in degrees Celsius.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed.</title>
        <description>Respiratory rate will be measured in breaths per minute.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed.</title>
          <description>Respiratory rate will be measured in breaths per minute.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed.</title>
        <description>Systolic and diastolic blood pressure will be measured in mmHg</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed.</title>
          <description>Systolic and diastolic blood pressure will be measured in mmHg</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed.</title>
        <description>Heart rate will be measured in beats per minute.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed.</title>
          <description>Heart rate will be measured in beats per minute.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.</title>
        <description>Plasma aPTT will be measured in seconds.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.</title>
          <description>Plasma aPTT will be measured in seconds.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.</title>
        <description>Prothrombin time will be measured in seconds.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.</title>
          <description>Prothrombin time will be measured in seconds.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>Bilirubin (total and direct) levels in the blood will be measured in mg/dL.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>Bilirubin (total and direct) levels in the blood will be measured in mg/dL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>Alkaline phosphatase levels in the blood will be measured in U/L.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>Alkaline phosphatase levels in the blood will be measured in U/L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>AST levels in the blood will be measured in U/L.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>AST levels in the blood will be measured in U/L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>ALT levels in the blood will be measured in U/L.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>ALT levels in the blood will be measured in U/L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>LDH levels in the blood will be measured in U/L.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>LDH levels in the blood will be measured in U/L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>Albumin levels in the blood will be measured in g/dL.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>Albumin levels in the blood will be measured in g/dL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>Sodium levels will be measured in mEq/L.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>Sodium levels will be measured in mEq/L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Potassium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>Potassium levels will be measured in mEq/L.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Potassium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>Potassium levels will be measured in mEq/L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Chloride Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>Chloride levels will be measured in mEq/L.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Chloride Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>Chloride levels will be measured in mEq/L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>Blood glucose levels will be measured in mg/dL.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>Blood glucose levels will be measured in mg/dL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Creatinine Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
        <description>Creatinine levels will be measured in mg/dL.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Creatinine Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.</title>
          <description>Creatinine levels will be measured in mg/dL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
        <description>Hemoglobin levels will be measured in g/dL.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
          <description>Hemoglobin levels will be measured in g/dL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Hematocrit Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
        <description>Hematocrit levels will be measured in %.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Hematocrit Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
          <description>Hematocrit levels will be measured in %.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
        <description>Total leukocyte counts will be measured in 10˄3/uL.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
          <description>Total leukocyte counts will be measured in 10˄3/uL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
        <description>Differential leukocyte counts will be measured in %.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
          <description>Differential leukocyte counts will be measured in %.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
        <description>Red blood cell count will be measured in 10˄6/uL.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
          <description>Red blood cell count will be measured in 10˄6/uL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Platelet Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
        <description>Platelet count will be measured in 10˄3/uL.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Platelet Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.</title>
          <description>Platelet count will be measured in 10˄3/uL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine pH, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>pH of the urine will be measured.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine pH, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>pH of the urine will be measured.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>Specific gravity of the urine will be evaluated.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>Specific gravity of the urine will be evaluated.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine Protein Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>Protein levels in the urine will be evaluated.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine Protein Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>Protein levels in the urine will be evaluated.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>Glucose levels in the urine will be evaluated.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>Glucose levels in the urine will be evaluated.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>Ketone levels in the urine will be evaluated.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>Ketone levels in the urine will be evaluated.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>Bilirubin levels in the urine will be evaluated.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>Bilirubin levels in the urine will be evaluated.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine Blood Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>Blood levels in the urine will be evaluated.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine Blood Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>Blood levels in the urine will be evaluated.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>Nitrite levels in the urine will be evaluated.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>Nitrite levels in the urine will be evaluated.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>Urobilinogen levels in the urine will be evaluated.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>Urobilinogen levels in the urine will be evaluated.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
        <description>Leukocyte esterase levels in the urine will be evaluated.</description>
        <time_frame>21 days</time_frame>
        <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).</title>
          <description>Leukocyte esterase levels in the urine will be evaluated.</description>
          <population>Only one subject in the study was able to produce urine. The rest were anuric.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome).</title>
        <description>Assessment of thrombus accumulation in the dialyzer cartridge measured by visual inspection.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome).</title>
          <description>Assessment of thrombus accumulation in the dialyzer cartridge measured by visual inspection.</description>
          <units>Complete occlusions of filter</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose hemodialysis (days -7, -5, -3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose hemodialysis (days 1, 3, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome).</title>
        <description>Assessment of BUN (mg/dL) before and after hemodialysis as urea reduction ratio (URR), %.</description>
        <time_frame>21 days</time_frame>
        <population>In a few instances, the pre- and post-dialysis values appeared to be switched and were excluded from the summary statistics or a value was missing or not reportable.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome).</title>
          <description>Assessment of BUN (mg/dL) before and after hemodialysis as urea reduction ratio (URR), %.</description>
          <population>In a few instances, the pre- and post-dialysis values appeared to be switched and were excluded from the summary statistics or a value was missing or not reportable.</population>
          <units>URR (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose Day -7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.53" spread="4.734"/>
                    <measurement group_id="O2" value="70.59" spread="7.361"/>
                    <measurement group_id="O3" value="69.61" spread="6.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day -5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.98" spread="4.927"/>
                    <measurement group_id="O2" value="70.36" spread="5.759"/>
                    <measurement group_id="O3" value="70.37" spread="6.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day -3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="6.624"/>
                    <measurement group_id="O2" value="67.04" spread="10.576"/>
                    <measurement group_id="O3" value="68.73" spread="6.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.82" spread="6.201"/>
                    <measurement group_id="O2" value="69.37" spread="10.440"/>
                    <measurement group_id="O3" value="71.36" spread="6.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.47" spread="5.496"/>
                    <measurement group_id="O2" value="72.14" spread="5.613"/>
                    <measurement group_id="O3" value="70.33" spread="6.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.63" spread="5.972"/>
                    <measurement group_id="O2" value="71.42" spread="6.944"/>
                    <measurement group_id="O3" value="71.86" spread="5.864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.66" spread="8.039"/>
                    <measurement group_id="O2" value="72.34" spread="6.749"/>
                    <measurement group_id="O3" value="70.98" spread="6.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV.</title>
        <description>Assessment of BUN (mg/dL) before and after hemodialysis as KtV (mL/min).</description>
        <time_frame>21 days</time_frame>
        <population>In a few instances, the pre- and post-dialysis values appeared to be switched and were excluded from the summary statistics or a value was missing or not reportable.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV.</title>
          <description>Assessment of BUN (mg/dL) before and after hemodialysis as KtV (mL/min).</description>
          <population>In a few instances, the pre- and post-dialysis values appeared to be switched and were excluded from the summary statistics or a value was missing or not reportable.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose Day -7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.312" spread="0.1537"/>
                    <measurement group_id="O2" value="1.449" spread="0.3051"/>
                    <measurement group_id="O3" value="1.413" spread="0.2359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day -5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.250" spread="0.1615"/>
                    <measurement group_id="O2" value="1.402" spread="0.2467"/>
                    <measurement group_id="O3" value="1.432" spread="0.2253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day -3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.330" spread="0.2078"/>
                    <measurement group_id="O2" value="1.337" spread="0.3887"/>
                    <measurement group_id="O3" value="1.347" spread="0.2239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.386" spread="0.2311"/>
                    <measurement group_id="O2" value="1.438" spread="0.4005"/>
                    <measurement group_id="O3" value="1.492" spread="0.2424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.399" spread="0.1894"/>
                    <measurement group_id="O2" value="1.509" spread="0.2505"/>
                    <measurement group_id="O3" value="1.431" spread="0.2482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.393" spread="0.1841"/>
                    <measurement group_id="O2" value="1.494" spread="0.3209"/>
                    <measurement group_id="O3" value="1.451" spread="0.2383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.253" spread="0.2267"/>
                    <measurement group_id="O2" value="1.527" spread="0.3107"/>
                    <measurement group_id="O3" value="1.478" spread="0.2480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome).</title>
        <description>Assessment of plasma potassium (mEq/L) before and after hemodialysis. The reduction of plasma potassium (before hemodialysis minus after hemodialysis) is reported in mEq/L).</description>
        <time_frame>21 days</time_frame>
        <population>In a few instances, the pre- and post-dialysis values appeared to be switched and were excluded from the summary statistics or a value was missing or not reportable.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome).</title>
          <description>Assessment of plasma potassium (mEq/L) before and after hemodialysis. The reduction of plasma potassium (before hemodialysis minus after hemodialysis) is reported in mEq/L).</description>
          <population>In a few instances, the pre- and post-dialysis values appeared to be switched and were excluded from the summary statistics or a value was missing or not reportable.</population>
          <units>mEq/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose Day -7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.648"/>
                    <measurement group_id="O2" value="1.60" spread="0.595"/>
                    <measurement group_id="O3" value="1.69" spread="0.722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day -5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.769"/>
                    <measurement group_id="O2" value="1.44" spread="0.802"/>
                    <measurement group_id="O3" value="1.71" spread="0.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day -3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.668"/>
                    <measurement group_id="O2" value="1.41" spread="0.308"/>
                    <measurement group_id="O3" value="1.63" spread="0.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.405"/>
                    <measurement group_id="O2" value="1.66" spread="0.862"/>
                    <measurement group_id="O3" value="2.05" spread="1.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.603"/>
                    <measurement group_id="O2" value="1.81" spread="0.521"/>
                    <measurement group_id="O3" value="1.58" spread="0.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.504"/>
                    <measurement group_id="O2" value="1.70" spread="0.751"/>
                    <measurement group_id="O3" value="1.99" spread="0.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.566"/>
                    <measurement group_id="O2" value="1.45" spread="0.389"/>
                    <measurement group_id="O3" value="1.39" spread="0.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodialysis Efficiency as Measured by Length of the Hemodialysis Session (Pharmacodynamic Outcome).</title>
        <description>The length of each hemodialysis session will be recorded.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodialysis Efficiency as Measured by Length of the Hemodialysis Session (Pharmacodynamic Outcome).</title>
          <description>The length of each hemodialysis session will be recorded.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose Day -7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235" spread="8.44"/>
                    <measurement group_id="O2" value="237" spread="4.84"/>
                    <measurement group_id="O3" value="240" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day -5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240" spread="7.75"/>
                    <measurement group_id="O2" value="234" spread="8.89"/>
                    <measurement group_id="O3" value="240" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day -3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242" spread="4.60"/>
                    <measurement group_id="O2" value="239" spread="3.54"/>
                    <measurement group_id="O3" value="240" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233" spread="15.9"/>
                    <measurement group_id="O2" value="232" spread="15.6"/>
                    <measurement group_id="O3" value="240" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240" spread="0.00"/>
                    <measurement group_id="O2" value="235" spread="12.6"/>
                    <measurement group_id="O3" value="240" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240" spread="0.00"/>
                    <measurement group_id="O2" value="239" spread="1.77"/>
                    <measurement group_id="O3" value="240" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232" spread="14.1"/>
                    <measurement group_id="O2" value="239" spread="3.18"/>
                    <measurement group_id="O3" value="240" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of a Single Intravenous Dose of Xisomab 3G3 on the Activated Partial Thromboplastin Time (aPTT) (Pharmacodynamic Outcome).</title>
        <description>aPTT will be measured as a pharmacodynamic marker and the change from baseline will be summarized using descriptive statistics.</description>
        <time_frame>21 days</time_frame>
        <population>In one instance, the aPTT value was missing or not reportable.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of a Single Intravenous Dose of Xisomab 3G3 on the Activated Partial Thromboplastin Time (aPTT) (Pharmacodynamic Outcome).</title>
          <description>aPTT will be measured as a pharmacodynamic marker and the change from baseline will be summarized using descriptive statistics.</description>
          <population>In one instance, the aPTT value was missing or not reportable.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" spread="7.90"/>
                    <measurement group_id="O2" value="42.2" spread="4.84"/>
                    <measurement group_id="O3" value="39.1" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.167h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" spread="19.7"/>
                    <measurement group_id="O2" value="92.3" spread="11.8"/>
                    <measurement group_id="O3" value="42.5" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" spread="18.8"/>
                    <measurement group_id="O2" value="91.9" spread="12.8"/>
                    <measurement group_id="O3" value="38.2" spread="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9" spread="22.3"/>
                    <measurement group_id="O2" value="91.4" spread="12.5"/>
                    <measurement group_id="O3" value="38.2" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" spread="23.3"/>
                    <measurement group_id="O2" value="89.9" spread="11.4"/>
                    <measurement group_id="O3" value="38.5" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" spread="21.5"/>
                    <measurement group_id="O2" value="93.7" spread="4.5"/>
                    <measurement group_id="O3" value="39.3" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" spread="21.5"/>
                    <measurement group_id="O2" value="96.0" spread="11.7"/>
                    <measurement group_id="O3" value="41.5" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" spread="19.9"/>
                    <measurement group_id="O2" value="92.5" spread="10.1"/>
                    <measurement group_id="O3" value="39.4" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="19.490"/>
                    <measurement group_id="O2" value="83.9" spread="5.2"/>
                    <measurement group_id="O3" value="38.1" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" spread="17.7"/>
                    <measurement group_id="O2" value="86.1" spread="8.2"/>
                    <measurement group_id="O3" value="41.4" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" spread="17.9"/>
                    <measurement group_id="O2" value="84.1" spread="9.10"/>
                    <measurement group_id="O3" value="40.7" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" spread="21.7"/>
                    <measurement group_id="O2" value="89.6" spread="10.1"/>
                    <measurement group_id="O3" value="36.9" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" spread="20.9"/>
                    <measurement group_id="O2" value="85.3" spread="7.30"/>
                    <measurement group_id="O3" value="37.0" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" spread="10.8"/>
                    <measurement group_id="O2" value="83.5" spread="27.2"/>
                    <measurement group_id="O3" value="40.1" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" spread="16.3"/>
                    <measurement group_id="O2" value="66.3" spread="16.9"/>
                    <measurement group_id="O3" value="46.1" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="5.4"/>
                    <measurement group_id="O2" value="59.4" spread="23.3"/>
                    <measurement group_id="O3" value="39.8" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" spread="5.5"/>
                    <measurement group_id="O2" value="52.6" spread="17.2"/>
                    <measurement group_id="O3" value="39.0" spread="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>264h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="8.019"/>
                    <measurement group_id="O2" value="46.6" spread="9.94"/>
                    <measurement group_id="O3" value="39.6" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Maximum Plasma Concentration (Cmax) of Xisomab 3G3 After a Single Injection Will be Measured in Each Patient (Pharmacokinetic Outcome).</title>
        <description>Maximum plasma concentration of xisomab 3G3</description>
        <time_frame>14 days</time_frame>
        <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Plasma Concentration (Cmax) of Xisomab 3G3 After a Single Injection Will be Measured in Each Patient (Pharmacokinetic Outcome).</title>
          <description>Maximum plasma concentration of xisomab 3G3</description>
          <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1918" spread="120.6"/>
                    <measurement group_id="O2" value="7557" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to Reach Maximum Plasma Concentrations of Xisomab 3G3 (Tmax) After a Single Injection Will be Measured in Each Patient (Pharmacokinetic Outcome).</title>
        <description>The time to reach maximum plasma concentrations of xisomab 3G3 after a single injection.</description>
        <time_frame>14 days</time_frame>
        <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Reach Maximum Plasma Concentrations of Xisomab 3G3 (Tmax) After a Single Injection Will be Measured in Each Patient (Pharmacokinetic Outcome).</title>
          <description>The time to reach maximum plasma concentrations of xisomab 3G3 after a single injection.</description>
          <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" lower_limit="0.167" upper_limit="3.00"/>
                    <measurement group_id="O2" value="0.750" lower_limit="0.167" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Patient (Pharmacokinetic Outcome)</title>
        <description>The area under the plasma concentration-time curve from time 0 to the last measurable non-zero concentration.</description>
        <time_frame>14 days</time_frame>
        <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Patient (Pharmacokinetic Outcome)</title>
          <description>The area under the plasma concentration-time curve from time 0 to the last measurable non-zero concentration.</description>
          <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22330" spread="214.7"/>
                    <measurement group_id="O2" value="256300" spread="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
        <description>The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
        <time_frame>14 days</time_frame>
        <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
          <description>The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
          <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39010" spread="101.5"/>
                    <measurement group_id="O2" value="273200" spread="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of AUC0-inf Extrapolated (AUC%Extrap) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
        <description>The percent of AUC0-inf extrapolated (AUC%extrap) is calculated by (1-AUC0-t/AUC0-inf)*100.</description>
        <time_frame>14 days</time_frame>
        <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of AUC0-inf Extrapolated (AUC%Extrap) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
          <description>The percent of AUC0-inf extrapolated (AUC%extrap) is calculated by (1-AUC0-t/AUC0-inf)*100.</description>
          <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.55" spread="11.619"/>
                    <measurement group_id="O2" value="5.846" spread="8.0195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Apparent First Order Terminal Elimination Rate Constant (Kel) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject (Pharmacokinetic Outcome).</title>
        <description>The apparent first order terminal elimination rate constant will be calculated from a semi-log plot of the plasma concentration versus time curve. The parameter will be calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).</description>
        <time_frame>14 days</time_frame>
        <population>zOne subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
        </group_list>
        <measure>
          <title>The Apparent First Order Terminal Elimination Rate Constant (Kel) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject (Pharmacokinetic Outcome).</title>
          <description>The apparent first order terminal elimination rate constant will be calculated from a semi-log plot of the plasma concentration versus time curve. The parameter will be calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).</description>
          <population>zOne subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08800" spread="0.073260"/>
                    <measurement group_id="O2" value="0.03027" spread="0.010510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Apparent First Order Terminal Elimination Half-life (T1/2) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
        <description>The apparent first order terminal elimination half-life will be calculated as 0.693/Kel.</description>
        <time_frame>14 days</time_frame>
        <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
        </group_list>
        <measure>
          <title>The Apparent First Order Terminal Elimination Half-life (T1/2) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
          <description>The apparent first order terminal elimination half-life will be calculated as 0.693/Kel.</description>
          <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.125" spread="5.3961"/>
                    <measurement group_id="O2" value="27.082" spread="15.1722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Apparent Total Plasma Clearance (CL) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
        <description>The apparent total plasma clearance will be calculated as [Dose/AUC0-inf].</description>
        <time_frame>14 days</time_frame>
        <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
        </group_list>
        <measure>
          <title>The Apparent Total Plasma Clearance (CL) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
          <description>The apparent total plasma clearance will be calculated as [Dose/AUC0-inf].</description>
          <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="773.6" spread="612.47"/>
                    <measurement group_id="O2" value="155.0" spread="42.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Apparent Volume of Distribution (Vss) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
        <description>The total apparent volume of distribution (Vss) will be calculated as the mean residence time x clearance.</description>
        <time_frame>14 days</time_frame>
        <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>AB023 (Xisomab 3G3)- Dose 1</title>
            <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
          </group>
          <group group_id="O2">
            <title>AB023 (Xisomab 3G3)- Dose 2</title>
            <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Apparent Volume of Distribution (Vss) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Patient (Pharmacokinetic Outcome).</title>
          <description>The total apparent volume of distribution (Vss) will be calculated as the mean residence time x clearance.</description>
          <population>One subject (0.25 mg/kg xisomab 3G3) was excluded from the summary statistics since the 0.17 hr Xisomab 3G3 concentration was suspected to be an outlier. One subject (0.25 mg/kg xisomab 3G3) had an AUC%extrap that was very high (63%) and therefore was excluded.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9945" spread="5014.8"/>
                    <measurement group_id="O2" value="5498" spread="793.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from study check in (Day -8) through the final follow up (Day 12) for a total of 21 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AB023 (Xisomab 3G3)- Dose 1</title>
          <description>Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
AB023- Dose 1: Participants will receive a single dose of 0.25 mg/kg AB023.</description>
        </group>
        <group group_id="E2">
          <title>AB023 (Xisomab 3G3)- Dose 2</title>
          <description>Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
AB023-Dose 2: Participants will receive a single dose of 0.5 mg/kg AB023.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants will receive a single dose of placebo.
placebo: Participants will receive a single dose of placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Aronora, Inc. shall retain title to and the right to publish all documentation, records, raw data, specimens, or other work product generated in connection with this study. Such publications shall not be made by the PI or Celerion without the prior written consent of Aronora, Inc.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christina U. Lorentz</name_or_title>
      <organization>Aronora, Inc.</organization>
      <phone>503-964-0250</phone>
      <email>christina.lorentz@aronorabio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

